Interleukin-1 blockade in refractory giant cell arteritis

Joint Bone Spine

Volumn 81, Issue 1, 2014, Pages 76-78

  Ly, Kim Heang ^a   Stirnemann, JérÔme ^b   Liozon, Eric ^a   Michel, Marc ^c   Fain, Olivier ^b   Fauchais, Anne Laure ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b Service de Medecine Interne Jean Verdier   (France)

^c HÔpital Henri Mondor   (France)

Author keywords

Case report; Giant cell arteritis; Interleukin 1 blockade

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; DAPSONE; ETANERCEPT; GALLIUM 67; GLUCOCORTICOID; INTERLEUKIN 1; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; DEXCHLORPHENIRAMINE; GLUCOSE; MYCOPHENOLIC ACID;

ACHILLES TENDON RUPTURE; AGED; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ARTERY THROMBOSIS; ARTICLE; CASE REPORT; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FRAGILITY FRACTURE; GIANT CELL ARTERITIS; GLUCOSE TRANSPORT; HEADACHE; HEPATITIS; HUMAN; JAUNDICE; JAW PAIN; MALE; NIGHT SWEAT; OFF LABEL DRUG USE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSITRON EMISSION TOMOGRAPHY; PRURITUS; PYREXIA IDIOPATHICA; RADIODENSITOMETRY; REFRACTORY GIANT CELL ARTERITIS; SHOULDER PAIN; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; VISUAL DISORDER; WEIGHT REDUCTION; WHOLE BODY CT; ANTAGONISTS AND INHIBITORS; SCINTISCANNING; ANTICOAGULANT THERAPY; AORTA; ARTERIOGRAPHY; BLINDNESS; BLOOD VESSEL BIOPSY; CAROTIDODYNIA; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DOPPLER ECHOGRAPHY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; HUMAN TISSUE; LOW DRUG DOSE; NECK PAIN; PAIN; PELVIC GIRDLE PAIN; PHYSICAL EXAMINATION; SCINTIANGIOGRAPHY; STENT THROMBOSIS; SUBCLAVIAN ARTERY; SUBCLAVIAN ARTERY STENT; TEMPORAL ARTERY; TEMPORAL ARTERY BIOPSY;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; FEMALE; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84893793527     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.06.004     Document Type: Article

References (15)

1. Proven A., Gabriel S.E., Orces C., et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703-708.
2. Hernandez-Rodriguez J., Segarra M., Vilardell C., et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004, 43:294-301.
3. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621-630.
4. Seitz M., Reichenbach S., Bonel H.M., et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011, 141:w13156.
5. Shepherd J., Nicklin M.J. Elastic-vessel arteritis in interleukin-1 receptor antagonist-deficient mice involves effector Th1 cells and requires interleukin-1 receptor. Circulation 2005, 111:3135-3140.
6. Masson C. Therapeutic approach to giant cell arteritis. Joint Bone Spine 2012, 79:219-227.
7. Mahr A.D., Jover J.A., Spiera R.F., et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007, 56:2789-2797.
8. Martinez-Taboada V.M., Rodriguez-Valverde V., Carreno L., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630.
9. Vinit J., Bielefeld P., Muller G., et al. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine 2012, 79:317-318.
10. Puechal X., Guillevin L. Therapeutic immunomodulation in systemic vasculitis: taking stock. Joint Bone Spine 2012, 10.1016/jbspin.2012.10.023.
11. Unizony S., Arias-Urdaneta L., Miloslavsky E., et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012, 64:1720-1729.
12. Nuki G., Bresnihan B., Bear M.B., et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:2838-2846.
13. Pountain G., Hazleman B., Cawston T.E. Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis. Br J Rheumatol 1998, 37:797-798.
14. Horai R., Saijo S., Tanioka H., et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000, 191:313-320.
15. Aksentijevich I., Masters S.L., Ferguson P.J., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009, 360:2426-2437.